Glenmark Pharma’s $1.9 Billion Breakthrough!

Glenmark Pharmaceuticals

just made headlines with the biggest-ever out-licensing deal by an Indian pharma firm. The stock jumped over 15% intraday after it signed a $1.9 billion licensing agreement with US-based AbbVie for a new cancer drug — ISB 2001. Deal Snapshot: $700 million upfront, with milestone payouts of up to $1.225 billion Tiered royalties on future sales Total deal size: ₹16,000 crore — more than Glenmark’s full-year FY25 revenue! What’s ISB 2001? It’s an early-stage drug for multiple myeloma, a type of blood cancer that affects over 1.5 lakh patients in the US. With treatment costs nearing ₹2.5 crore per patient/year, the global market is worth $24 billion. Even a small share means billions in future cashflows. The drug is in Phase 1 trials, but has already received fast-track status from the US FDA, thanks to promising early results. Why it Matters: This move flips the narrative. Glenmark’s innovation arm, once seen as a cash-burner, has now delivered three big partnerships. Analysts believe this could trigger a stock re-rating. Technicals & Trends: Stock trading above 20, 50 & 200 DMA Strong bullish volume surge 2Y / 3Y / 5Y breakout RSI shows bullish crossover Still, caution is warranted. Recent results showed falling profit, EPS, and margins. The core business faces cash flow issues, and PE remains high (>40) with negative ROE. Investor Takeaway: This deal is a game-changer, but the drug is still early in its journey. Glenmark now has a chance to move from generic pharma to global biotech recognition — but execution will be key. Learning Point: Out-licensing can unlock hidden value in R&D-heavy companies. Keep an eye on pipeline progress and market potential — not just current earnings.